<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00795808</url>
  </required_header>
  <id_info>
    <org_study_id>UAuckland</org_study_id>
    <nct_id>NCT00795808</nct_id>
  </id_info>
  <brief_title>PCOSMIC Trial - PolyCystic Ovary Syndrome, Metformin for Infertility With Clomiphene</brief_title>
  <acronym>PCOSMIC</acronym>
  <official_title>Multi-Centre Randomised Controlled Trial of the Effectiveness of Metformin and Clomiphene Citrate for Treating Anovulatory Infertility in Women With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Auckland, New Zealand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Auckland Medical Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mercia Barnes Trust of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Auckland, New Zealand</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Metformin increases the pregnancy rate when added to the standard treatment of
           anovulatory polycystic ovary syndrome (PCOS).

        2. Metformin in combination with clomiphene, is more effective than clomiphene alone or
           metformin alone improves fertility outcomes in women with PCOS of reasonably healthy
           body weight (BMI &lt;/= 32).

        3. Metformin improves fertility outcomes in women with BMI &gt; 32 with PCOS.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2003</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical pregnancy</measure>
    <time_frame>within 6 calendar months of randomisation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Live birth</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">171</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>BMI &gt; 32</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women with BMI &gt; 32</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BMI &lt;/= 32</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women with BMI &lt;/= 32</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>500mg tds for 6 months</description>
    <arm_group_label>BMI &gt; 32</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One tablet tds for 6 months</description>
    <arm_group_label>BMI &gt; 32</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin + Clomiphene</intervention_name>
    <description>500mg tds + Ovulatory dose for 6 months</description>
    <arm_group_label>BMI &lt;/= 32</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>500mg tds for 6 months</description>
    <arm_group_label>BMI &lt;/= 32</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clomiphene</intervention_name>
    <description>Ovulatory dose for 6 months</description>
    <arm_group_label>BMI &lt;/= 32</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women between the age of 18 and 39 years inclusive.

          -  Anovulatory infertility of duration at least 12 months.

          -  Polycystic ovary syndrome, based on Rotterdam consensus criteria.

          -  Normal serum prolactin, thyroid function and 17-hydroxyprogesterone.

          -  Normal serum prolactin, thyroid function and 17-hydroxyprogesterone;

        Exclusion Criteria:

          -  Presence of any other significant infertility factor including male factor, known
             tubal disease or history of an ectopic pregnancy, known endometriosis affecting the
             fallopian tubes or ovaries.

          -  Already taking oral hypoglycaemics.

          -  Diabetics receiving treatment.

          -  Renal impairment

          -  Chronic hepatic disease

          -  Cardiac Disease

          -  Alcohol dependency

          -  Pre-disposition to lactic acidosis

          -  Previous ovarian drilling procedure, gonadotrophin injection therapy, IUI
             (intrauterine insemination) or IVF ( in vitro fertilisation).

          -  For those women who have had previous fertility treatment, the following would be
             excluded:

               -  Women who have had &gt; 5 cycles of clomiphene citrate

               -  Women who have had &gt; 5 months metformin treatment previously

               -  Women who have proven to be resistant to 100mg or more of clomiphene citrate.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil P Johnson, FRANZCOG</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Auckland, fertility Plus &amp; Repromed Auckland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Auckland</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2008</study_first_submitted>
  <study_first_submitted_qc>November 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2008</study_first_posted>
  <last_update_submitted>November 20, 2008</last_update_submitted>
  <last_update_submitted_qc>November 20, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2008</last_update_posted>
  <responsible_party>
    <name_title>Associate Professor Neil Johnson</name_title>
    <organization>University of Auckland, Fertility Plus and Repromed Auckland</organization>
  </responsible_party>
  <keyword>Polycystic ovary syndrome</keyword>
  <keyword>PCOS</keyword>
  <keyword>Anovulation</keyword>
  <keyword>Infertility</keyword>
  <keyword>Anovulatory polycystic ovary syndrome (PCOS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

